Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Renaissance and GlaxoSmithKline Agree to a Transfer of Nine Products



  Renaissance and GlaxoSmithKline Agree to a Transfer of Nine Products

Business Wire

MONTREAL & RESEARCH TRIANGLE PARK, N.C. -- June 3, 2013

Renaissance Acquisition Holdings, LLC (“Renaissance”), a RoundTable Healthcare
Partners (“RoundTable”) portfolio company, and GlaxoSmithKline (LSE: GSK)
(NYSE: GSK) announced today that they have entered into an agreement giving
Renaissance the rights in the USA to manufacture, market and sell six
dermatology and three anti-viral products from GSK.

The products from GSK and Stiefel, a GSK company, which will be marketed
through Renaissance’s branded division Prestium Pharma (“Prestium”), include:

 1. Evoclin® (clindamycin phosphate) Foam, 1%
 2. Extina® (ketoconazole) Foam, 2%
 3. Luxiq® (betamethasone valerate) Foam, 0.12%
 4. Olux® (clobetasol propionate) Foam, 0.05%
 5. Olux-E® (clobetasol propionate) Foam, 0.05%
 6. Vusion® (miconazole nitrate 0.25%, zinc oxide 15% and white petrolatum
    81.35%) Ointment
 7. Zovirax® (acyclovir) Capsules
 8. Zovirax® (acyclovir) Tablets
 9. Zovirax® (acyclovir) Suspension

Pierre Fréchette, President and CEO of Renaissance, stated, “This transaction
represents a significant milestone for Renaissance, and is in-line with our
strategy of acquiring niche products that we can both manufacture within our
internal network and market through our strong commercial group. The
RoundTable team was instrumental in helping to source, diligence and complete
such an important acquisition.”

Simon Jose, Stiefel President, said, “This agreement allows US patients to
continue to have access to treatments they value and allows the Stiefel US
Team to focus on growth and development of new treatments within our core
dermatology portfolio.”

John Denman, General Manager of Prestium, commented, “We are excited to add
these mature specialty brands to Prestium’s growing portfolio, and look
forward to continuing to supply such important products to our customers and
to patients across the country.”

About Renaissance Acquisition Holdings

Renaissance Acquisition Holdings focuses on two pharmaceutical industry
segments in the United States and Canada: 1) contract development and
manufacturing, and 2) commercialization of branded and generic prescription
products. For more information, visit www.RenaissanceAH.com.

About Prestium Pharma, Inc.

Prestium Pharma, a subsidiary of Renaissance Acquisition Holdings, focuses on
acquiring, licensing and selling in-market branded prescription products,
including mature brands with or without generic competition. More information
about Prestium can be found at www.PrestiumPharma.com.

About GSK

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and
healthcare companies – is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For further
information, please visit www.gsk.com.

About Stiefel, a GSK company

Stiefel, a GSK company, is committed to advancing Dermatology and skin science
around the world in order to help people better achieve healthier skin.
Stiefel’s dedication to innovation, along with its focus on pharmaceutical and
over-the-counter Dermatology products, has established Stiefel as a world
leader in the skin health industry. To learn more about Stiefel, visit
www.stiefel.com.

About RoundTable Healthcare Partners

RoundTable Healthcare Partners, based in Lake Forest, IL, is an
operating-oriented private equity firm focused exclusively on the healthcare
industry. RoundTable partners with companies that can benefit from its
extensive industry relationships and proven operating and transaction
expertise. RoundTable has established a successful track record of working
with owner/founders, family companies, management teams, entrepreneurs and
corporate partners who share a vision and believe in the value creation
potential of its partnership model. RoundTable currently manages $1.9 billion
in capital, including three equity funds totaling $1.5 billion and two
subordinated debt funds totaling $400 million. More information about
RoundTable Healthcare Partners can be found at www.roundtablehp.com.

Contact:

Prestium
John Denman, 267-685-0340
or
GlaxoSmithKline US Media
Robin Gaitens, 919-483-2678
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement